Demographic and clinical characteristics of 213 patients with RA
| Variables | Scores |
| Age, years, mean (SD) | 57.8 (13.2) |
| Female gender, n (%) | 172 (80.8) |
| Disease duration, years, mean (SD) | 11.8 (8.9) |
| Rheumatoid factor positive, n (%)* | 154 (72.3) |
| Anticitrullinated antibody positive, n (%)* | 101 (70.6) |
| Comorbidities, yes, n (%) | |
| Fibromyalgia* | 35 (16.4) |
| Depression* | 38 (17.8) |
| Low back pain* | 40 (18.8) |
| Osteoporotic fractures* | 16 (7.5) |
| Osteoarthritis* | 108 (50.7) |
| Stroke* | 4 (1.9) |
| Current treatment with biologic agents, n (%) | 66 (31) |
| Tender joint counts using 28 joints (0–28), mean (SD) | 1.52 (3.2) |
| Swollen joint counts using 28 joints (0–28), mean (SD) | 1.46 (2.7) |
| C reactive protein, CRP (mg/dL), mean (SD) | 0.81 (1.4) |
| Disease Activity, DAS28CRP3v (0–9.4), mean (SD) | 2.48 (0.93) |
| Remission, n (%) | 127 (59.6) |
| Low, n (%) | 49 (23) |
| Moderate, n (%) | 34 (16) |
| High, n (%) | 3 (1.4) |
| Physician global assessment (VAS, 0–100), mean (SD) | 14.2 (15. 9) |
| Patient global assessment (VAS, 0–100), mean (SD) | 47.5 (28.6) |
| Rheumatoid Arthritis Impact of Disease (0–10), mean (SD) | |
| Pain | 4.8 (2.5) |
| Functional disability | 4.9 (2.6) |
| Fatigue | 5.1 (2.7) |
| Emotional well-being | 4.6 (2.7) |
| Sleep | 4.4 (2.9) |
| Coping | 4.2 (2.7) |
| Physical well-being | 4.9 (2.5) |
| EuroQOL five dimensions (−0.59 to 1), mean (SD) | 0.43 (0.26) |
| Subjective Happiness Scale (1–7), mean (SD) | 4.8 (1.3) |
| Ten-Item Personality Inventory (1–7), mean (SD) | |
| Extraversion | 4.1 (1.5) |
| Agreeableness | 5.7 (1.3) |
| Conscientiousness | 5.6 (1.3) |
| Emotional stability | 3.7 (1.5) |
| Openness to experience | 4.4 (1.5) |
*Percentages of patients with missing data were <2.8%, except for ACPA (32.8%) and erosions (18.8%), fibromyalgia (7%), depression (7.5%), low back pain (10.3%), osteoporotic fractures (19.7%), osteoarthritis (8.9%) and stroke (8.5%).